Theorem Clinical Research

Drug Sponsors

Endo to acquire Dava Pharmaceuticals

Wednesday, June 25, 2014 01:50 PM

Endo International has reached a definitive agreement to acquire Dava Pharmaceuticals, a privately held company specializing in marketed, pre-launch and pipeline generic pharmaceuticals, for $575 million in cash, with additional cash consideration of up to $25 million contingent on the achievement of certain sales milestones. The acquisition enhances Endo's commercialization and development platform and is expected to be immediately accretive to Endo's 2014 adjusted earnings per share (EPS).

More... »

Quest Diagnostics

Dart Therapeutics changes name to Akashi Therapeutics

Wednesday, June 25, 2014 01:46 PM

Dart Therapeutics has changed its name to Akashi Therapeutics to reflect its progress in developing a pipeline of product candidates to improve the lives of children with Duchenne muscular dystrophy (DMD).

More... »


Shire confirms rejection of AbbVie proposal

Friday, June 20, 2014 01:47 PM

Shire has confirmed it has rejected the May 30 unsolicited and highly conditional proposal from AbbVie regarding a possible cash and share offer for Shire. 

More... »

Celsion completes acquisition of Egen

Friday, June 20, 2014 01:04 PM

Celsion, an oncology drug development company, has completed its acquisition of substantially all of the assets of Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases. The acquisition includes Egen’s phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

SillaJen Biotherapeutics completes name change

Friday, June 20, 2014 01:01 PM

SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

More... »

Pfizer opens new R&D site in Cambridge, Mass.

Tuesday, June 17, 2014 11:08 AM

Pfizer has announced the opening of a new 280,000-square-foot R&D hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and positions Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.

More... »

Medtronic to acquire Covidien for $42.9 billion

Monday, June 16, 2014 09:43 AM

Medtronic, a global medical technology, services and solutions company, has agreed to acquire Covidien, a global healthcare technology and medical supplies provider, in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic’s closing stock price of $60.70 per share on June 13. 

More... »

EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »

Novo Nordisk to add 6,000 new jobs in Denmark by 2022

Friday, June 13, 2014 01:10 PM

Global healthcare company Novo Nordisk expects to hire 6,000 new employees in Denmark through 2022, half of whom will work within R&D. According to a Novo Nordisk report, the new jobs will have the derived effect of boosting employment by more than 15,000 jobs nationally.

More... »

Cardiovascular Systems plans new corporate headquarters

Friday, June 13, 2014 01:07 PM

Cardiovascular Systems, a medical device company, has plans to build a new corporate headquarters in New Brighton, Minn. The 125,000-square-foot, two-story building will have space for more than 500 employees and contain dedicated R&D, training and education and manufacturing facilities. CSI’s headquarters will be located in the New Brighton Exchange, approximately 10 minutes from downtown Minneapolis.

More... »

AiCure
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs